Pharmaceutical, Clinical, and Regulatory Challenges of Reformulating Pressurized Metered-Dose Inhalers to Reduce Their Environmental Impact
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2025
DOI: 10.1089/jamp.2024.0023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2025. Verfasst von Nicolas Roche und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Institut Cochin, INSERM UMR 1016, Paris, France. Hauptthemen laut MEDLINE: Metered Dose Inhalers, Aerosol Propellants, Chlorofluorocarbons. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The chlorofluorocarbons (CFCs) that were used as propellants in early pressurized metered-dose inhalers (pMDIs) had substantial ozone-depleting potential. Following the Montreal Protocol in 1987, the manufacture of a range of ozone-depleting substances, including CFCs, was gradually phased out, which required the propellants used in pMDIs to be replaced. Current pMDIs use hydrofluoroalkanes (HFAs) as propellants, such as 1,1,1,2-tetrafluoroethane (HFA-134a). Although these HFAs have no ozone-depleting potential, they have a high global warming potential (GWP), and consequently, their use is being phased down. One option for the discontinuation of HFA use in inhalers would be to discontinue all pMDIs, switching patients to dry powder inhalers (DPIs). However, a switch from pMDIs to DPIs may not be a clinically appropriate option for some patients; furthermore, the full lifecycle carbon footprint and the overall environmental impact of different inhalers should be considered. An alternative is therefore to reformulate the current HFA pMDIs to use low-GWP propellants, such as 1,1-difluoroethane (HFA-152a). This article summarizes the various steps and challenges associated with this change, illustrated using data from the inhaled triple combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide, a complex formulation of three molecules in a solution that contains liquid-phase propellant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Institut Cochin, INSERM UMR 1016, Paris, France.
- Inserm, Équipe d'Épidémiologie Respiratoire Intégrative, CESP, Villejuif, France.
- NHLI Imperial College London, London, United Kingdom.
- Chiesi Farmaceutici SpA, Parma, Italy.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen, The Netherlands.
- Medication Adherence Expertise Center of the northern Netherlands (MAECON), Groningen, The Netherlands.
ORCID-Profile: Sara Panigone
Zitieren
APA
Roche, N., Usmani, O., Franzini, L., Labadini, L., Mathews, K. S., Panigone, S., & van Boven, J. F. M. (2025). Pharmaceutical, Clinical, and Regulatory Challenges of Reformulating Pressurized Metered-Dose Inhalers to Reduce Their Environmental Impact. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2024.0023
Vancouver
Roche N, Usmani O, Franzini L, Labadini L, Mathews KS, Panigone S, et al. Pharmaceutical, Clinical, and Regulatory Challenges of Reformulating Pressurized Metered-Dose Inhalers to Reduce Their Environmental Impact. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2025. doi:10.1089/jamp.2024.0023
BibTeX
@article{Roche2025,
author = {Roche, Nicolas and Usmani, Omar and Franzini, Laura and Labadini, Lorenza and Mathews, Kusum S and Panigone, Sara and van Boven, Job F M},
title = {Pharmaceutical, Clinical, and Regulatory Challenges of Reformulating Pressurized Metered-Dose Inhalers to Reduce Their Environmental Impact},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2025},
doi = {10.1089/jamp.2024.0023}
}
EUVIMED